Australia's Amplia Therapeutics up on funding to advance cancer trial
** Shares of Amplia Therapeutics ATX.AX rise as much as
8.8% to A$0.062; set to gain most since April 19, if current
trends hold
** Drug developer completes A$4.27 million ($2.83 million)
capital raise
** Co says funds will be used for the ongoing Phase 2 ACCENT
trial in pancreatic cancer
** Adds, ongoing Phase 2a ACCENT trial in advanced
pancreatic cancer patients is progressing to plan
** Stock hits highest level since May 9
** Stock has fallen 26.7% this year, as of last close
($1 = 1.5063 Australian dollars)
(Reporting by Rajasik Mukherjee in Bengaluru)
((Rajasik.Mukherjee@thomsonreuters.com;))
Recent news on Amplia Therapeutics
See all newsBrief: Amplia Therapeutics Signs Collaboration And Supply Agreement With Lilly
Australia's Amplia rises to 4-month high on Eli Lilly cancer drug trial collaboration
Brief: Amplia Therapeutics Says Warwick Tong Will Retire As Board Chairman
Brief: Amplia Therapeutics Reports Four Additional Complete Responses And Improved Overall Survival Data In Accent Pancreatic Cancer Trial
Brief: Amplia Therapeutics Requests Trading Halt Pending Clinical Trial Results Announcement